Elite Pharmaceuticals, Inc.

Total Valuation

Elite Pharmaceuticals, Inc. carries a market capitalization of 399.06M, placing it among publicly traded companies globally. Its enterprise value stands at 364.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Elite Pharmaceuticals, Inc. currently has 1.08B shares outstanding.

Valuation Ratios

Elite Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 8.65. The price-to-sales ratio is 2.61, and the price-to-book ratio stands at -5.19.

Enterprise Valuation

On an enterprise value basis, Elite Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 7.01 and an EV/FCF ratio of 14.58. The EV/Sales ratio of 2.45 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 7.29 provides insight into valuation relative to core operating earnings.

Financial Position

Elite Pharmaceuticals, Inc. maintains a current ratio of 6.45, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.88, indicating elevated leverage, while an interest coverage ratio of 131.04 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Elite Pharmaceuticals, Inc. has paid 11.94M in income taxes, reflecting an effective tax rate of 21.02.

Stock Price Statistics

Elite Pharmaceuticals, Inc.'s stock has declined approximately -32.63636% over the past 52 weeks. The 50-day moving average sits at 0.37, while the 200-day moving average is 0.45.

Income Statement

Over the trailing twelve months, Elite Pharmaceuticals, Inc. generated 148.87M in revenue and converted that into 44.87M in net income, yielding earnings per share of 0.04. EBITDA reached 51.98M, while operating income came in at 49.96M.

Balance Sheet

Elite Pharmaceuticals, Inc. holds 29.80M in cash and equivalents against 5.82M in total debt, resulting in a net debt position of -26.76M. Total book value stands at -74.75M, with working capital of 94.72M providing operational flexibility.

Cash Flow

Elite Pharmaceuticals, Inc. produced 23.75M in operating cash flow over the past twelve months. After subtracting -925,626.00 in capital expenditures, free cash flow totaled 22.82M - equivalent to 0.02 per share.

Margins

Elite Pharmaceuticals, Inc. operates with a gross margin of 50.40, reflecting its pricing power and cost economics. The operating margin of 33.56 and net profit margin of 30.14 provide insight into operational efficiency.

Dividends & Yields

Scores

Elite Pharmaceuticals, Inc. posts an Altman Z-Score of 8.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.